Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT07405216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Centenario Hospital Miguel Hidalgo
- Registry
-
NCT07405216
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Recruiting
Technical summary
Registry record NCT07405216. Randomized; triple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2027-05-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
- Acronym
- IECA-MEX
- Condition
- Chronic Kidney Disease (Mild to Moderate)
- Condition
- Albuminuria
- Condition
- Adolescent
- Condition
- Sodium Glucose Co-Transporter 2 Inhibitors
- Intervention (Drug)
- Dapagliflozin (10mg Tab)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Centenario Hospital Miguel Hidalgo
Record details
- Record id
cardio:ct-nct07405216- Content hash
f1a15769bc30c9c109a6538b40011f8da14aa4fa0505efcff6d5feb39c1d894c